WO1996017899A1 - Anti-oxidant compositions - Google Patents
Anti-oxidant compositions Download PDFInfo
- Publication number
- WO1996017899A1 WO1996017899A1 PCT/GB1995/002888 GB9502888W WO9617899A1 WO 1996017899 A1 WO1996017899 A1 WO 1996017899A1 GB 9502888 W GB9502888 W GB 9502888W WO 9617899 A1 WO9617899 A1 WO 9617899A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- oxidant
- composition
- amphiphile
- phase
- solvent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L3/00—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs
- A23L3/34—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals
- A23L3/3454—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals in the form of liquids or solids
- A23L3/3463—Organic compounds; Microorganisms; Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/676—Ascorbic acid, i.e. vitamin C
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K15/00—Anti-oxidant compositions; Compositions inhibiting chemical change
- C09K15/04—Anti-oxidant compositions; Compositions inhibiting chemical change containing organic compounds
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11B—PRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES
- C11B5/00—Preserving by using additives, e.g. anti-oxidants
- C11B5/0021—Preserving by using additives, e.g. anti-oxidants containing oxygen
- C11B5/0028—Carboxylic acids; Their derivates
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11B—PRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES
- C11B5/00—Preserving by using additives, e.g. anti-oxidants
- C11B5/0042—Preserving by using additives, e.g. anti-oxidants containing nitrogen
- C11B5/005—Amines or imines
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11B—PRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES
- C11B5/00—Preserving by using additives, e.g. anti-oxidants
- C11B5/0071—Preserving by using additives, e.g. anti-oxidants containing halogens, sulfur or phosphorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/522—Antioxidants; Radical scavengers
Definitions
- the present invention relates to compositions comprising an anti-oxidant solubilised in a hydrophobic solvent in which it would not normally be soluble.
- the present invention relates to compositions comprising ascorbic acid solubilised in a hydrophobic solvent in which it would not normally be soluble.
- anti-oxidants For many applications, e.g. in the pharmaceutical sciences, in food technology or the cosmetics industry, it is desired (and in certain cases essential) to employ anti-oxidants to limit oxidation of, for instance, an active ingredient or food ingredient.
- Anti-oxidants can be divided into two main functional groups, the chelating agents which act by sequestering pro-oxidant ions, such as those of transition metals, while the second group are the free radical scavengers (chain-oreakers), which have the effect of interrupting oxidative chain reactions.
- the latter may operate in a hy ⁇ ropnilic (normally aqueous) or a hydrophobic (e.g. lipid) environment, depending on their solubility characteristics.
- lipid-soluble, free-radical scavengers include natural anti-oxidants such as ⁇ -tocopnerol and ⁇ -carotene, as well as synthetic ones, e.g. BHA and BHT.
- Ascorbic acid (Vitamin C) is a water-soluble free-radical scavenger (and thus will normally operate in this mode only in the aqueous phase), but it also has an important role as a chelating anti-oxidant. Yet another, very important anti-oxidant action of ascorbic acid is that it can interact synergistically with ⁇ -tocopherol, thus resulting in a greatly increased component anti-oxidant activities. In this relationship, ⁇ -tocopnerol functions as the primary anti-oxidant which is able to repair a lipid free radical, thus interrupting the oxidation chain reaction while itself being converted to a free radical in the process. Ascorbic acid acts by regenerating the tocopheroxyl radical, thus restoring its anti-oxidant function. Synergistic relationships are also known to occur between other anti-oxidant species, but often different mechanisms apply.
- a requirement for ascorbic acid/ ⁇ -tocopherol synergistic action is that in order to interact, the two species must be able to come into close contact. This can be difficult in view of the fact that ascorbic acid is water soluble while ⁇ -tocopherol is lipid soluble. Such interactions may occur in a living cell since tocopherols are usually present in membranes which are in intimate contact with the aqueous cytoplasmic phase. It is therefore possible to duplicate this type of interaction in vitro using liposomes in place of biological membranes.
- a further available strategy is that of using a lipid- soluble derivative of ascorbic acid such as ascorbyl palmitate, which does interact synergistically with ⁇ -tocopnerol.
- ascorbyl palmitate is not very soluble and can require heat to dissolve, which paradoxically increases oxidative susceptibility of vulnerable compounds, for example polyunsaturates, and this therefore mitigates against its use in situations where these compounds are required to be protected, for example in the preparation of certain foodstuffs.
- UK patent application No. 9323588.5 discloses a process by which a hydrophilic species can be solubilised in a hydrophobic solvent in which it would not normally be soluble.
- the process relies on the surprising discovery that if a hydrophilic species is mixed with an amphiphile under certain conditions, the resultant composition will be readily soluble in lipophilic solvents such as oils.
- compositions comprising an anti-oxidant solubilised in a hydrophobic solvent in which it would not normally be soluble, are effective as anti-oxidant compositions.
- anti-oxidant species retain their anti-oxidant properties in such a non-aqueous environment .
- the present invention provides an anti-oxidant composition comprising at least one anti-oxidant species solubilised in a hydrophobic solvent in which it would not normally be soluble.
- the compositions of the invention will be anhydrous.
- an anti-oxidant preparation is provided which does not contain water.
- the anti-oxidant species is selected from ascorbic acid, citric acid, phytic acid, pyrophospnate, EDTA, transferrin, ceruplasmin, metallothionein, albumin, haptoglobin, cysteine, glutathione, conjugated bile pigments (e.g. bilirubin and biliverdin), uric acid, vanillic acid, vanillin, and Trolox.
- conjugated bile pigments e.g. bilirubin and biliverdin
- uric acid vanillic acid
- vanillin vanillin
- Trolox conjugated bile pigments
- the anti-oxidant is selected from ascorbic acid, cysteine, glutathione, conjugated bile pigments and uric acid.
- a particularly preferred anti-oxidant is ascorbic acid.
- solubilised refers to the anti-oxidant species being held in the hydrophobic solvent, in the ansence of water, i.e. without the need for any water to be present.
- compositions of the present invention thus provide an anti-oxidant in a non-aqueous form to protect materials from oxidation, since it has been surprisingly found that such compositions are effective as a means of protecting against oxidation notwithstanding that the anti-oxidant is solubilised in a nydrophobic solvent
- compositions according to the invention are useful in that it is possible to provide lipid soluble anti-oxidants, e.g. vitamin E, in combination with one or more water soluble anti-oxidants, such as ascorbic acid, which act synergistically with vitamin E, thus providing an enhanced anti-oxidant composition.
- lipid soluble anti-oxidants e.g. vitamin E
- water soluble anti-oxidants such as ascorbic acid
- the present invention provides an anti-oxidant composition
- an anti-oxidant composition comprising a lipid soluole anti-oxidant species, together with one or more anti-oxidants solubilised in a hydropnobic solvent in which the one or more other anti-oxidants would not normally be soluble.
- the lipid soluble anti-oxidant species can be selected from tocopherols (e.g. ⁇ -tocopherol), ⁇ -carotene, d ⁇ tocotrienol, quercetin, acacetin, BHA, BHT, TBHQ, propyl gallate and probucol.
- the lipid soluble anti-oxidant species is a tocopherol, particularly ⁇ -tocopherol, and the other anti-oxidant is one which can act synergistically with ⁇ -tocopherol, resulting in enhanced anti-oxidant activity, e.g. ascorbic acid, cysteine, glutathione, conjugated bile pigments or uric acid.
- compositions of the present invention can be prepared using the processes described in UK patent application No. 9323588.5.
- the present invention provides a process for the preparation of a single phase hydrophobic anti-oxidant preparation comprising at least one antioxidant species solubilised in a hydrophobic solvent in which it would not normally be soluble, the process comprising:
- the process can be halted at the end of stage (ii) and the resulting material can be stored under appropriate conditions until it is needed to generate the single-phase preparation by providing a hydrophobic solvent.
- the term "chemical interaction” relates to an interaction such as a covalent or ionic bond or a hydrogen bond. It is not intended to include van der Waals forces or other interactions of that order of magnitude.
- This process can also be used to produce a composition comprising vitamin E together with one or more other anti-oxidants which act synergistically with vitamin E, and which are not normally soluble in a hydrophobic solvent, to enhance anti-oxidant activity.
- vitamin E can be added at either or both of stages (i) and (iii) described above.
- amphiphiles which may be used to prepare the compositions of the present invention and zwitterionic amphiphiles such as phospholipids are among those which have been found to be especially suitable.
- Phospholipids having a phosphatidyl choline head group have been used with particular success and examples of such phospholipids include phosphatidyl choline (PC) itself, lyso-phosphatidyl choline (lyso-PC), sphingomyelin, derivatives of any of these, for example hexadecylphospnocholine or amphiphilic polymers containing phosphoryl choline and halogenated amphiphiles, e.g. fluorinated phospholipids.
- PC phosphatidyl choline
- lyso-PC lyso-phosphatidyl choline
- sphingomyelin derivatives of any of these, for example hexadecylphospnocho
- phosphatidyl choline PC
- lecithin Suitable natural lecithins may be derived from any convenient source, for example egg and, in particular, soya. In most cases, it is preferable to select an amphiphile which is chemically similar to the chosen hydrophobic solvent and this is discussed in greater detail below.
- the hydropnobic solvent of choice will depend on the purpose for which the composition is intended, on the anti-oxidant species to be solubilised and on the amphiphile.
- Suitable solvents include non-polar oils such as mineral oils, squalane and squalene, long chain fatty acids with unsaturated fatty acids such as oieic and linoleic acids being preferred, alconols, particularly medium chain alcohols such as octanol and branched long chain alcohols sucn as pnytol, isoprenoids, e.g.
- nerol and geraniol other alcohols such as t-butanol, terpineoi, monoglycendes such as glycerol monooleate (GMO), other esters, e.g. ethyl acetate, amyl acetate and bornyl acetate, digiycerides and triglycerides, particularly medium chain triglycerides and mixtures thereof, Halogenated analogues of any of the above including halogenated oils, e.g. long chain fluorocarbons, and iodinated triglycerides, e.g. lipidiol. In particular, polyunsaturated oils or saturated oils are preferred.
- hydrophobic solvent and the amphiphile are appropriately matched.
- a solvent such as oleic acid
- lyso-PC is a more effective choice of amphiphile than PC
- the converse is true when the hydrophobic solvent is a triglyceride.
- the preparations cf the invention are optically clear and this can be monitored by measuring turbidity at visual wave lengths and, in some cases, by checking for sedimentation over a period of time.
- amphiphile molecules into an array with their hydrophilic head groups facing the moieties of an anti-oxidant species can be achieved in several ways and examples of particularly suitable methods are discussed in more detail below.
- an anti-oxidant species is mixed with a dispersion of an amphiphile in a hydrophilic solvent, such that the amphiphile molecules form an assembly in which the hydrophilic head groups face outwards towards the hydrophilic phase which contains the anti-oxidant species.
- the hydrophilic solvent is then removed to leave a dry composition in which the hydrophilic head groups of the amphiphile molecules are orientated towards the anti-oxidant species.
- the hydrophilic solvent is water although other polar solvents may be used.
- the form taken by the amphiphile assembly may be micelles, unilamellar vesicles, preferably small unilamellar vesicles which are generally understood to have a diameter of about 25 nm, multilamellar vesicles or tubular structures, for example cochleate cylinders, hexagonal pnase, cubic phase or myelin type structures.
- the form adopted will depend upon the amphiphile which is used and, for example, amphiphiles such as phosphatidyl choline (PC) tend to form small unilamellar vesicles wnereas lyso-phosphatidyl choline forms micelles.
- the hydrophobic tails of the amphiphile molecules face inwards towards the centre of the structure while the hydrophilic head groups face outwards towards the solvent in whicn the anti-oxidant species is dispersed.
- the weight ratio of amphiphile : anti -oxidant species will generally be in the region of from 1:1 to 100:1, preferably from 2:1 to 20:1 and most preferably about 8:1 for PC and 4:1 for lyso-PC. These ratios are preferred ratios only and, in particular, it should be pointed out that the upper limit is set by economic considerations which mean that it is preferable to use the minimum possible amount of amphiphile.
- the lower limit is somewhat more critical and it is likely that ratios of 2:1 or below would only be used in cases where the anti-oxidant species has a significant hydrophobic portion or is exceptionally large. Good performance is obtained when the solvent is removed quickly and a convenient method for the removal of the solvent is lyophilisation, although other methods can be used.
- a second method for the preparation of a composition containing an array of amphiphiles with their nead groups pointing towards the anti-oxidant species is to co-soiubiiise the anti-oxidant species and the amphiphile in a common solvent followed by removal of the solvent.
- solutions of the present invention may either be used alone or they may be combined with an aqueous phase to form an emulsion or similar two pnase composition wnich forms yet a further aspect of the invention.
- a two phase composition comprising a hydrophilic phase and a hydropnobic phase, the hydrophobic phase comprising a preparation of an anti-oxidant species as described herein .
- the hydropnobic phase will be dispersed in the hydrophilic phase.
- the two phase compositions may be emulsions which may either be transient or stable, depending on the purpose for which they are required.
- the average size of the emulsion particles will depend on the exact nature of both the hydrophobic and the aqueous phases. However, it may be in the region of 2 ⁇ m
- Dispersion of the hydrophobic preparation in the aqueous phase can be achieved by mixing, for example either by vigourous vortexing for a short time for example about 10 to 60 seconds, usually about 15 seconds, or by gentle mixing for several hours, for example using an orbital shaker.
- Emulsions containing the hydrophobic preparations cf the invention can also be used in the preparation of microcapsules. If the emulsion is formed from a gelatin-containing aqueous phase, the gelatin can be precipitated from the solution by coacervation o ⁇ known metho ⁇ s and will form a film around the ⁇ roplets of the anti-oxidant-containing hydrophobic phase. On removal of the hydrophilic phase, microcapsules will remain. This technology is known in the art, but has proved particularly useful in combination with the preparations of the present invention.
- the invention provides. (i) the use of an anti-oxidant composition of the invention in the preparation of a pharmaceutical or cosmetic formulation or a foodstuff; (ii) a method for reducing oxidation of a pharmaceutical or cosmetic formulation or foodstuff which comprises adding an anti-oxidant composition of the invention to the pharmaceutical or cosmetic formulation or foodstuff; (iii) a composition comprising at least one anti-oxidant species solubilised in a hydrophobic solvent in which it would not normally be soluble, for use as an anti-oxidation agent; and (iv) the use of a composition of the invention in the preparation of an anti-oxidation agent.
- Example 3 refers to the figures in which:
- FIGURE 1 shows a comparison of oxidation index
- ratio of non-saturated fatty acid remaining in oil compared to amount of non-oxidisable interval standard for preparations with and without ascorbic acid alone or in combination with ⁇ -tocopherol.
- FIGURE 2 shows a comparison of oxidation index for preparations with and without ascorbic acid in the presence of linoleic acid and linoleic acid and Soy
- FIGURE 3 shows a comparison of oxidation index for preparations with and without ascorbic acid alone and with linoleic acid.
- EXAMPLE 1 2 rows of 4 small test-tubes were set up, and 0.2ml aliquots of 3.75, 7.5, 15 and 30mM ascorbic acid solutions were added to tubes 1, 2, 3 and 4 respectively, across each row.
- 0.2 ml of soy PC SUVs, prepared as in Example 2 was added to each tube in the front row, and 0.2 ml of distilled water to each tube in the second row.
- the tube contents were shell-frozen in liquid nitrogen and freeze-dried overnight.
- To each lyophilate in the first row was added 200mg of Miglyol 818, while 200mg of a solution comprising 10% soy PC in Miglyol 818 was added to each tube in the second row.
- aqueous dispersion of soy phosphatidyl choline was prepared, containing 50mg/g of suspension, flushed thoroughly with nitrogen, and sonicated in 3ml aliquots at an amplitude of 8 microns peak to peak. Each aliquot was subjected to a total sonication time of 4 minutes, in pulses of 30 seconds interspersed by cooling for 30 seconds in an ice slurry bath.
- the resulting opalescent dispersions of small unilamellar vesicles (SUV) were pooled and then centrifuged for 15 minutes to remove particles of titanium.
- a trilinolein/linoleic acid/PC oil phase of similar composition but lacking ascorbic acid was prepared by freeze-drying 0.7g of SUV and then dissolving the lyophilate in 1.75g of the same trilinolein/linoleic acid solution.
- a low ascorbate dispersion was prepared by diluting 0.25g of the high ascorbate one with 750mg of the above oil phase.
- Into 3 small glass vials were added aliquots of 0.6, 0.6 and 0.5mg respectively of ⁇ -tocopherol. For reasons of accuracy, this was added as a 0.6% ethanolic solution, the ethanol being subsequently removed under a stream of nitrogen.
- fatty acid components in each vial were then converted to methyl ester derivatives by standard procedures and measured by GC. Results were expressed in terms of an Oxidation Index, which is defined here as the percentage of remaining 18 : 2 fatty acids (derived from trilinolein and linoleic acid) relative to 17 : 0 fatty acids (heptadecanoic acid).
- EXAMPLE 4 An aqueous phospnolipid dispersion was prepared containing 100mg soy PC/g and converted to SUV as described in Example 3. Appropriate amounts of SUV were mixed with aqueous 1% ascorbic acid solutions to provide mixtures having PC : ascorbic acid ratios of 13.33 : 1, and tne mixtures were shell-frozen and freeze-dried. The resulting lyophilates were mixed with refined fish oil containing 2% w/w of linoleic acid (as a solubilisation enhancer) to give clear dispersions containing 1.5 or 3.0 mg ascorbic acid/g of oil phase.
- Control oil phases were also prepared comprising pure fish oil, and also fish oil containing 2% linoleic acid both in the absence and presence of 2% w/w of dissolved soy PC de in the same concentration as in the dispersion containing 1.5mg ascorbic acid/g).
- the two ascorbic acid-containing dispersions, and the three oil phase controls, were each distributed as 50mg aliquots into crimpable glass chromatography vials as in Example 3, and again stored uncapped in a 37 C incubator, le under conditions for accelerated oxidation of lipids.
- a lyophilate of soy PC and ascorbic acid was prepared as described in Example 4 and then mixed with sunflower oil containing 2% w/w of added linoleic acid to form a clear dispersion containing 1.5mg ascorbic acid/g of oil phase.
- Oil phase controls were prepared comprising pure sunflower oil and also sunflower oil containing 2% linoleic acid, in the absence and presence of 2% w/w of soy PC. 50mg aliquots of the ascorbic acid dispersion and of the 3 oil phase controls, were incubated under conditions for accelerated lipid oxidation as described in Example 4, and were sampled periodically and analysed in the same way. In this case however, the 18 : 2 fatty acid (linoleic acid) content was monitored.
- Results are plotted in Figure 3.
- the time course of oxidation of the soy PC-containing control oil phase was effectively identical to the equivalent control lacking PC, and was not plotted.
- the reason for the accelerated oxidation of the oil controls containing free linoleic acid, compared with pure sunflower oil where the endogenous linoleic acia is in a conjugated form, is not clear.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Wood Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Microbiology (AREA)
- Emergency Medicine (AREA)
- Nutrition Science (AREA)
- Materials Engineering (AREA)
- Polymers & Plastics (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Anti-Oxidant Or Stabilizer Compositions (AREA)
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP95940348A EP0796302A1 (en) | 1994-12-09 | 1995-12-08 | Anti-oxidant compositions |
AU41826/96A AU700084B2 (en) | 1994-12-09 | 1995-12-08 | Anti-oxidant compositions |
NZ297052A NZ297052A (en) | 1994-12-09 | 1995-12-08 | Antioxidant composition comprising an antioxidant solubilised in a hydrophobic solent in which it would not normally be soluble |
JP8517434A JPH10510563A (en) | 1994-12-09 | 1995-12-08 | Antioxidant composition |
FI972421A FI972421A (en) | 1994-12-09 | 1997-06-06 | Antioxidant compositions |
NO972609A NO972609L (en) | 1994-12-09 | 1997-06-06 | antioxidant Preparations |
MXPA/A/1997/004273A MXPA97004273A (en) | 1994-12-09 | 1997-06-09 | Antioxidant compositions |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9424908.3A GB9424908D0 (en) | 1994-12-09 | 1994-12-09 | Anti-Oxidant Compositions |
GB9424908.3 | 1994-12-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1996017899A1 true WO1996017899A1 (en) | 1996-06-13 |
Family
ID=10765697
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1995/002888 WO1996017899A1 (en) | 1994-12-09 | 1995-12-08 | Anti-oxidant compositions |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP0796302A1 (en) |
JP (1) | JPH10510563A (en) |
CN (1) | CN1168687A (en) |
AU (1) | AU700084B2 (en) |
CA (1) | CA2207325A1 (en) |
FI (1) | FI972421A (en) |
GB (1) | GB9424908D0 (en) |
IL (1) | IL116312A0 (en) |
NO (1) | NO972609L (en) |
NZ (1) | NZ297052A (en) |
WO (1) | WO1996017899A1 (en) |
ZA (1) | ZA9510506B (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6278004B1 (en) | 1996-11-06 | 2001-08-21 | Aventis Pharma Deutschland Gmbh | Stabilized phospholipidic composition |
US6368619B1 (en) | 1993-11-16 | 2002-04-09 | Provalis Uk Limited | Hydrophobic preparations of hydrophilic species and process for their preparation |
US6458373B1 (en) | 1997-01-07 | 2002-10-01 | Sonus Pharmaceuticals, Inc. | Emulsion vehicle for poorly soluble drugs |
US7030155B2 (en) | 1998-06-05 | 2006-04-18 | Sonus Pharmaceuticals, Inc. | Emulsion vehicle for poorly soluble drugs |
EP1889597A1 (en) * | 2006-07-28 | 2008-02-20 | Beiersdorf AG | Active agent combinations of an ascorbyl compound and hydrogenated lecithin |
FR3012292A1 (en) * | 2013-10-24 | 2015-05-01 | Polaris | ANTIOXIDANT COMPOSITION FOR OXIDATIVE STABILIZATION OF MARINE OR ANIMAL OR VEGETABLE OILS |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8034372B2 (en) * | 2003-03-05 | 2011-10-11 | Nestec, Ltd. | Dietary supplement for athletic pets |
JP2008174512A (en) * | 2007-01-22 | 2008-07-31 | Kracie Seiyaku Kk | Composition for ameliorating exhausted feeling at time of rising |
US20140308733A1 (en) * | 2011-09-08 | 2014-10-16 | Calpis Co., Ltd. | Method for inducing germination of spore forming bacterium |
CN103876243B (en) * | 2012-12-21 | 2015-11-11 | 贵州天刺力食品科技有限责任公司 | Compound antioxidant |
CN103518975B (en) * | 2013-10-23 | 2015-01-21 | 麦仑(漳州)生物科技有限公司 | Compound antioxidant for animal feeds as well as preparation method of compound antioxidant |
WO2019038161A1 (en) * | 2017-08-25 | 2019-02-28 | Dsm Ip Assets B.V. | New formulation |
CN108379094B (en) * | 2018-04-24 | 2021-09-14 | 广州暨南大学医药生物技术研究开发中心有限公司 | Composition containing bioactive cosmetic polypeptide lipid cubic crystal and application of composition in cosmetics |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0326829A2 (en) * | 1988-02-03 | 1989-08-09 | Societe Des Produits Nestle S.A. | Synergetic antioxidant mixture |
US5077069A (en) * | 1991-01-07 | 1991-12-31 | Kabi Pharmacia Ab | Composition of natural antioxidants for the stabilization of polyunsaturated oils |
WO1992000019A1 (en) * | 1990-06-26 | 1992-01-09 | Kalamazoo Holdings, Inc. | Activated ascorbic acid antioxidant compositions and carotenoids, fats, and foods stabilized therewith |
US5084289A (en) * | 1989-02-01 | 1992-01-28 | Korea Food Research Institute | Method for the inhibition of oxidation of edible oils utilizing a fat soluble anti-oxidant and a water soluble anti-oxdant in a reverse micelle system |
EP0514576A1 (en) * | 1991-05-24 | 1992-11-25 | Societe Des Produits Nestle S.A. | Oil-soluble antioxidant mixture |
-
1994
- 1994-12-09 GB GBGB9424908.3A patent/GB9424908D0/en active Pending
-
1995
- 1995-12-08 WO PCT/GB1995/002888 patent/WO1996017899A1/en not_active Application Discontinuation
- 1995-12-08 AU AU41826/96A patent/AU700084B2/en not_active Ceased
- 1995-12-08 JP JP8517434A patent/JPH10510563A/en active Pending
- 1995-12-08 CA CA002207325A patent/CA2207325A1/en not_active Abandoned
- 1995-12-08 NZ NZ297052A patent/NZ297052A/en unknown
- 1995-12-08 CN CN95196630.8A patent/CN1168687A/en active Pending
- 1995-12-08 EP EP95940348A patent/EP0796302A1/en not_active Ceased
- 1995-12-10 IL IL11631295A patent/IL116312A0/en unknown
- 1995-12-11 ZA ZA9510506A patent/ZA9510506B/en unknown
-
1997
- 1997-06-06 NO NO972609A patent/NO972609L/en unknown
- 1997-06-06 FI FI972421A patent/FI972421A/en unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0326829A2 (en) * | 1988-02-03 | 1989-08-09 | Societe Des Produits Nestle S.A. | Synergetic antioxidant mixture |
US5084289A (en) * | 1989-02-01 | 1992-01-28 | Korea Food Research Institute | Method for the inhibition of oxidation of edible oils utilizing a fat soluble anti-oxidant and a water soluble anti-oxdant in a reverse micelle system |
WO1992000019A1 (en) * | 1990-06-26 | 1992-01-09 | Kalamazoo Holdings, Inc. | Activated ascorbic acid antioxidant compositions and carotenoids, fats, and foods stabilized therewith |
US5077069A (en) * | 1991-01-07 | 1991-12-31 | Kabi Pharmacia Ab | Composition of natural antioxidants for the stabilization of polyunsaturated oils |
EP0514576A1 (en) * | 1991-05-24 | 1992-11-25 | Societe Des Produits Nestle S.A. | Oil-soluble antioxidant mixture |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6368619B1 (en) | 1993-11-16 | 2002-04-09 | Provalis Uk Limited | Hydrophobic preparations of hydrophilic species and process for their preparation |
US6278004B1 (en) | 1996-11-06 | 2001-08-21 | Aventis Pharma Deutschland Gmbh | Stabilized phospholipidic composition |
US6458373B1 (en) | 1997-01-07 | 2002-10-01 | Sonus Pharmaceuticals, Inc. | Emulsion vehicle for poorly soluble drugs |
US6660286B1 (en) | 1997-01-07 | 2003-12-09 | Sonus Pharmaceuticals, Inc. | Emulsion vehicle for poorly soluble drugs |
US6667048B1 (en) | 1997-01-07 | 2003-12-23 | Sonus Pharmaceuticals, Inc. | Emulsion vehicle for poorly soluble drugs |
US6982282B2 (en) | 1997-01-07 | 2006-01-03 | Sonus Pharmaceuticals, Inc. | Emulsion vehicle for poorly soluble drugs |
US7030155B2 (en) | 1998-06-05 | 2006-04-18 | Sonus Pharmaceuticals, Inc. | Emulsion vehicle for poorly soluble drugs |
EP1889597A1 (en) * | 2006-07-28 | 2008-02-20 | Beiersdorf AG | Active agent combinations of an ascorbyl compound and hydrogenated lecithin |
FR3012292A1 (en) * | 2013-10-24 | 2015-05-01 | Polaris | ANTIOXIDANT COMPOSITION FOR OXIDATIVE STABILIZATION OF MARINE OR ANIMAL OR VEGETABLE OILS |
Also Published As
Publication number | Publication date |
---|---|
IL116312A0 (en) | 1996-03-31 |
AU4182696A (en) | 1996-06-26 |
FI972421A0 (en) | 1997-06-06 |
NO972609L (en) | 1997-08-08 |
ZA9510506B (en) | 1997-09-11 |
AU700084B2 (en) | 1998-12-24 |
NO972609D0 (en) | 1997-06-06 |
FI972421A (en) | 1997-08-06 |
GB9424908D0 (en) | 1995-02-08 |
EP0796302A1 (en) | 1997-09-24 |
MX9704273A (en) | 1997-09-30 |
NZ297052A (en) | 1999-05-28 |
CN1168687A (en) | 1997-12-24 |
CA2207325A1 (en) | 1996-06-13 |
JPH10510563A (en) | 1998-10-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Taladrid et al. | Effect of chemical composition and sonication procedure on properties of food-grade soy lecithin liposomes with added glycerol | |
US5968549A (en) | Solubilisation aids | |
Budilarto et al. | The supramolecular chemistry of lipid oxidation and antioxidation in bulk oils | |
AU700084B2 (en) | Anti-oxidant compositions | |
US5716639A (en) | Lipophilic carrier preparations | |
US5688528A (en) | Oil-in water emulsions | |
JP5728152B2 (en) | Dry liposome preparation | |
KR100835250B1 (en) | A Self-emulsifying carrier and the preparation method thereof | |
US10080803B2 (en) | Emulsified krill phospholipid compositions | |
JP2005532049A (en) | Liquid with nano-sized self-assembled structure | |
MXPA98001863A (en) | Microemuls | |
Li et al. | Cooperative antioxidative effects of zein hydrolysates with sage (Salvia officinalis) extract in a liposome system | |
Yi et al. | Surfactant concentration, antioxidants, and chelators influencing oxidative stability of water-in-walnut oil emulsions | |
JP3081226B2 (en) | Method for preventing oxidation of fats or fat-containing products | |
Kabri et al. | Formulation of sub‐micron emulsions containing docosahexaenoic acid esterified in triacylglycerols or phospholipids | |
JPH06279467A (en) | Phospholipid composition | |
MXPA97004273A (en) | Antioxidant compositions | |
CA2207274A1 (en) | Sequestration agents | |
Cuvelier et al. | Do antioxidants improve the oxidative stability of oil‐in‐water emulsions? | |
JP2514995B2 (en) | Composition for promoting absorption of substance by transdermal and transmucosal | |
JPH02203928A (en) | Glycerophospholipid composition intensified in surface active action | |
JPH0853690A (en) | Method of admixing water-soluble active ingredient with fat | |
JPH0899821A (en) | Skin external agent | |
Memoli et al. | Lipid peroxidation of l-α-phosphatidylcholine from fresh egg yolk and from soybean during liposome preparation and storage | |
MXPA97004272A (en) | Seized agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 95196630.8 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG US UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 297052 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1019970703629 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: 2207325 Country of ref document: CA Ref document number: 2207325 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 972421 Country of ref document: FI |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/1997/004273 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1995940348 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1995940348 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1019970703629 Country of ref document: KR |
|
WWR | Wipo information: refused in national office |
Ref document number: 1995940348 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1995940348 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1019970703629 Country of ref document: KR |